Clinical Trial Update: GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for GPED in relapsed/refractory or advanced Extranodal NK/T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Extranodal NK/T-cell Lymphoma | Phase 2 | Status: UNKNOWN